Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638053 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00638053 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 100 participants.
The verdict
NCT00638053, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the prevalence of GHD in patients who sustain a head injury or suffer a major traumatic event and to evaluate the efficacy of growth hormone (GH) therapy in the treatment of GHD caused by trauma or head injury
Interventions
- GENETIC somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638053
The ClinicalTrials.gov registry entry for NCT00638053 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin is the first listed.
NCT00638053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638053 about?
NCT00638053 is a clinical study titled "A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury". The purpose of this study is to assess the prevalence of GHD in patients who sustain a head injury or suffer a major traumatic event and to evaluate the efficacy of growth hormone (GH) therapy in the treatment of GHD caused by trauma or head injury
What is the current status of trial NCT00638053?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2002-11. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00638053?
The interventions under investigation include: somatropin (GENETIC).
Who is sponsoring clinical trial NCT00638053?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.